Travera Inc: Clinical Trials

4 trials sponsored by Travera Inc, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 terminated, 1 withdrawn. 1 Not applicable.

By phase and status

PhaseTrialsStatus
Not applicable1Recruiting 1

Follow Travera Inc: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
Mass-based response testing (MRT) - Appendiceal Cancer, Colorectal Adenocarcinoma
Not applicableRecruitingYale University202026-02-172026-07-21
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Stage III Breast Cancer, Stage IV Breast Cancer
WithdrawnTravera Inc2024-11-012024-11-25
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Pleural Effusion, Malignant, Ascites, Malignant
CompletedTravera Inc722022-07-152026-04-13
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
Multiple Myeloma in Relapse
TerminatedTravera Inc332019-02-112024-07-03

Conditions studied

Appendiceal Neoplasms (3)  ·  Anus Neoplasms (2)  ·  Breast Neoplasms (2)  ·  Carcinoma (2)  ·  Carcinoma, Hepatocellular (2)  ·  Carcinoma, Neuroendocrine (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Carcinoma, Renal Cell (2)  ·  Cholangiocarcinoma (2)  ·  Esophageal Neoplasms (2)  ·  Laryngeal Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Mesothelioma (2)  ·  Mouth Neoplasms (2)  ·  Neoplasms, Unknown Primary (2)

Countries

United States (3)

Top investigators

Cara Rosenbaum, M.D. (1)  ·  Kiran Turaga, MD (1)  ·  Mark Stevens, Ph.D. (1)  ·  Mark Stevens, Phd (1)  ·  Nikhil C Munshi, M.D. (1)  ·  Rob Kimmerling, Phd (1)  ·  Robert Kimmerling, Ph.D. (1)